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Abstract
Background: Ovarian cancer is associated with poor long-term survival due to late diagnosis and development of
chemoresistance. Tumour hypoxia is associated with many features of tumour aggressiveness including increased
cellular proliferation, inhibition of apoptosis, increased invasion and metastasis, and chemoresistance, mostly
mediated through hypoxia-inducible factor (HIF)-1α. While HIF-1α has been associated with platinum resistance in
a variety of cancers, including ovarian, relatively little is known about the importance of the duration of hypoxia.
Similarly, the gene pathways activated in ovarian cancer which cause chemoresistance as a result of hypoxia are
poorly understood. This study aimed to firstly investigate the effect of hypoxia duration on resistance to cisplatin in
an ovarian cancer chemoresistance cell line model and to identify genes whose expression was associated with
hypoxia-induced chemoresistance.
Methods: Cisplatin-sensitive (A2780) and cisplatin-resistant (A2780cis) ovarian cancer cell lines were exposed to
various combinations of hypoxia and/or chemotherapeutic drugs as part of a ‘hypoxia matrix’ designed to cover
clinically relevant scenarios in terms of tumour hypoxia. Response to cisplatin was measured by the MTT assay. RNA
was extracted from cells treated as part of the hypoxia matrix and interrogated on Affymetrix Human Gene ST 1.0
arrays. Differential gene expression analysis was performed for cells exposed to hypoxia and/or cisplatin. From this,
four potential markers of chemoresistance were selected for evaluation in a cohort of ovarian tumour samples by
RT-PCR.
Results: Hypoxia increased resistance to cisplatin in A2780 and A2780cis cells. A plethora of genes were differentially
expressed in cells exposed to hypoxia and cisplatin which could be associated with chemoresistance. In ovarian
tumour samples, we found trends for upregulation of ANGPTL4 in partial responders and down-regulation in
non-responders compared with responders to chemotherapy; down-regulation of HER3 in partial and non-responders
compared to responders; and down-regulation of HIF-1α in non-responders compared with responders.
Conclusion: This study has further characterized the relationship between hypoxia and chemoresistance in an ovarian
cancer model. We have also identified many potential biomarkers of hypoxia and platinum resistance and provided an
initial validation of a subset of these markers in ovarian cancer tissues.
Keywords: Hypoxia, Chemoresistance, Ovarian cancer, Cisplatin, Biomarkers
* Correspondence: lmmcevoy@tcd.ie
1Department of Histopathology TCD, Sir Patrick Dun’s Laboratory, Central
Pathology Laboratory, St James’s Hospital, Dublin 8, Ireland
2Department of Obstetrics and Gynaecology, Trinity Centre for Health
Sciences, St James’s Hospital, Dublin 8, Ireland
Full list of author information is available at the end of the article
© 2015 McEvoy et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
McEvoy et al. BMC Cancer  (2015) 15:547 
DOI 10.1186/s12885-015-1539-8
Background
Ovarian cancer has recently been described as the sev-
enth most common female cancer worldwide [1]. More-
over, it is the fifth most common cause of cancer death
in women, and the leading cause of death from gynaeco-
logical malignancy in the Western world [2]. The mor-
tality rate for ovarian cancer is quite high compared to
other gynaecological cancers, mainly due to late disease
presentation and the development of chemoresistance.
While the majority of patients (80 %) initially respond
well to chemotherapy, many patients relapse and be-
come chemoresistant [3].
Platinum agents work by inducing intra- and inter-
strand adducts in GC-rich regions of DNA [4], which in
turn activate apoptosis via the p53 pathway [5]. Several
mechanisms contribute to platinum resistance, including
reduction in the number of copper transporters which
pump the drug into the cell [6], increase in glutathione
and other proteins which ‘mop up’ platinum within the
cell [7], up-regulation of DNA repair mechanisms [8], and
increase in the ATPase transporters which pump drug out
of the cell [9].
Normal tissue oxygen tension is in the region of 4–1 %,
while hypoxia is <1 % [10]; tumour hypoxia is a common
feature of solid tumours, such as ovarian cancer. Several
mechanisms may contribute to the development of
tumour hypoxia. Rapid proliferation of tumour cells may
cause depletion of available oxygen, while erratically grow-
ing tumour cells can compress blood vessels, stilting the
flow of oxygenated blood to the tumour. In addition, rapid
tumour growth can mean that tumour cells can grow such
a distance away from blood vessels that they are beyond
the diffusion distance for oxygen and can become hypoxic.
Tumour hypoxia switches on genetic pathways that pro-
mote tumour aggressiveness, metastasis and chemoresis-
tance; patients with hypoxic tumours generally have a
poorer prognosis [11].
Tumour hypoxia induces activation of the hypoxia-
inducible factor-1 (HIF-1) pathway. The HIF-1 protein
belongs to the basic helix-loop-helix Per Ant Sim (PAS)
protein family [12, 13]. It is composed of a hypoxia-
regulated α subunit, and a non-hypoxia-regulated β subunit
[11]. In normal oxygen, hydroxylation of proline residues
within the HIF-1α oxygen dependent degradation domain
targets it for proteasomal degradation via the Von Hippel-
Lindau protein [11, 14]. However, in hypoxia, this does not
occur; the HIF-1α protein accumulates and binds to
hypoxia-regulated elements (HREs) contained within the
promoter region of many genes, such as those that regulate
metabolism, cell survival, angiogenesis and invasion [11].
Hypoxia induces resistance to a wide range of cyto-
toxic agents in a number of different cancer types in-
cluding ovarian cancer [15]. Hypoxia has been shown to
induce platinum resistance through interference with a
number of biological molecules such as L1-cell adhesion
molecule (L1-CAM) [16], signal transducer and activator
of transcription 3 (STAT3) [15] and p53 [17]. The pres-
ence of hypoxia, measured by tumour expression of
HIF-1α or surrogate markers of hypoxia such as glucose
transporter (GLUT)-1 or carbonic anhydrase 9 (CA9),
has been shown to be associated with poorer survival in
ovarian cancer patients [18, 19]. However, the correl-
ation of HIF-1α with clinical response is complex; in-
creased HIF-1α expression has also been linked to
improved survival [20].
While hypoxia has been previously shown to induce
chemoresistance in a number of cell line models, few
studies evaluate the influence of hypoxia on platinum re-
sistance in ovarian cancer. In addition, although several
previous studies have explored links between ovarian
cancer genes and hypoxia [21–23], to our knowledge
there is no published study which has carried out whole-
genome profiling of ovarian cancer cell lines that have
been exposed to hypoxia in combination with cytotoxic
chemotherapy. Furthermore, although HIF-1α is fre-
quently cited as a marker of hypoxia, its role in predict-
ing clinical response to hypoxia is unclear.
As hypoxia is being progressively revealed as an import-
ant factor in the development of chemoresistance, it is im-
portant to discover new hypoxia-associated biomarkers
which may be exploited for their prognostic and thera-
peutic potential in ovarian cancer. In order to explore the
relationship between platinum resistance and hypoxia, we
selected a paired cisplatin resistance ovarian cancer cell line
model (A2780/A2780cis) [24–26]. We developed a ‘hypoxia
exposure matrix’ which was based on potential clinical sce-
narios and exposed cells to hypoxia prior to and during
treatment with cisplatin and measured relative changes in
platinum resistance compared to cells treated in normal
oxygen conditions via the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay. We then took
cells that had been exposed to concomitant hypoxia and/or
platinum (cisplatin) without any prior exposure to hypoxia
and carried out whole genome profiling using Affymetrix
Human Gene 1.0 ST arrays. Following pathway analysis of
genes differentially expressed following exposure to
hypoxia/platinum, we selected genes which had been
linked to platinum resistance in the literature. We ex-
amined their expression in a cohort of serous papillary
ovarian tumour samples grouped according to response
to chemotherapy using reverse transcription polymer-
ase chain reaction (RT-PCR).
Methods
Cell culture
The human epithelial serous ovarian cancer cell lines
A2780 (cisplatin-sensitive) and A2780cis (cisplatin-resist-
ant) were purchased from the European Collection of Cell
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Cultures (ECACC, UK) and cultured in a humidified at-
mosphere at 37 °C, 5 % CO2. They were maintained in
RPMI 1640 medium (Sigma, UK) supplemented with 10 %
foetal bovine serum (FBS, Lonza, UK), 1 % penicillin/
streptomycin mixture (Lonza, UK) and 2 mM Glutamax
(Gibco, Biosciences, Ireland). In addition, A2780cis were
cultured in 1 μM cisplatin (Hospira, UK) every second pas-
sage in accordance with the ECACC guidelines. Cells were
regularly checked for signs of bacterial, fungal or mycoplas-
mal contamination.
Tumour samples
Paraffin embedded sections were cut from 35 tumour
specimens obtained following surgery for ovarian cancer.
Patients provided written informed consent for their
samples to be used and ethical approval was obtained
from the St James’s Hospital/the Adelaide and Meath
Hospital, Dublin incorporating the National Children’s
Hospital Research Ethics Committee, Dublin, Ireland.
The study was carried out in accordance with the
principles of the Declaration of Helsinki. Samples were
divided into responders, partial responders, and non-
responders based on their response to platinum/taxane-
based chemotherapy (Table 1).
Drug treatment
Cells were treated with cisplatin (Hospira, UK) that was
kindly donated by the compounding unit at St. James’s
Hospital, Dublin. It was received as a 1 mg/ml solution
and was freshly diluted in media to the desired stock
concentration directly before each experiment. A vehicle
control consisting of 1 mg/ml mannitol (Sigma, UK) and
9 mg/ml sodium chloride (Sigma, UK) was also freshly
prepared in media prior to each experiment. All drug
treatments were for 3 days.
Hypoxic exposure
Hypoxia (0.5 % O2, 5 % CO2) was achieved using the
INVIVO2 400 hypoxia workstation (Ruskinn, UK). For the
MTT assay experiments, cells were cultured in 96-well
microtitre plates (Sarstedt, Germany) at a concentration
of 5,000 cells/well for various time periods as part of a hyp-
oxia design matrix (Table 2). The matrix consisted of two
phases – pre-treatment (up to 5 days) and treatment
(3 days) (Fig. 1, Table 2). In the pre-treatment phase, cells
were either maintained in normal oxygen (normoxia) or ex-
posed to hypoxia for an acute (4 h) or chronic (5 days) time
period. During the treatment phase, the cells were treated
with cisplatin in either normoxia or hypoxia. Cells that had
had been exposed to hypoxia prior to drug treatment were
treated with cisplatin in either normoxia or hypoxia for the
entire duration of treatment. The effect of introduction of
hypoxia during drug treatment was investigated by challen-
ging hypoxia naïve cells (i.e. cells with no pre-exposure to
hypoxia) with concurrent cisplatin and hypoxia, either for
the full treatment period, or for part of the treatment
period (1 or 2 days, with the remainder in normoxia). For
RNA and protein extraction, cells were cultured in T75 tis-
sue culture flasks (Sarstedt, Germany) at a concentration of
3–6 × 104/cm2 (A2780) or 1 × 103–1 × 104/cm2 (A2780cis)
as per the ECACC guidelines. For drug treatments, cells
were briefly removed from the hypoxia chamber and
Table 1 Clinical characteristics of tumour samplesa based on
response to chemotherapy
Class Definition Stage/
Grade
Number of
Samples
Responders Recurrence >12 months following
completion of chemotherapy
4/3 1
4/2 1
3/3 4
3/2 5
2/3 2
1/3 2
1/- 1
Total 16
Partial
Responders
Recurrence between 6 – 12 months
following completion of
chemotherapy
4/- 1
3/3 5
3/2 2
3/- 1
-/3 1
−/− 1
Total 11b
Non-
Responders
Recurrence <6 months following
completion of chemotherapy
4/3 1
3/3 3
3/2 2
-/2 1
Total 7
aAll tumours were serous adenocarcinomas. Patients who were classed as
between two stages/grades are included in this table as the
higher stage/grade
bThis group included one recurrent primary peritoneal serous adenocarcinoma
-, no information available
Table 2 Design matrix of hypoxia/cisplatin treatments
Pre-treatment Treatment Day 1 Treatment Day 2 Treatment Day 3
(0 – 24 h) (24 – 48 h) (48 – 72 h)
Normoxia Normoxia Normoxia Normoxia
Normoxia Hypoxia Hypoxia Hypoxia
Normoxia Normoxia Hypoxia Hypoxia
Normoxia Normoxia Normoxia Hypoxia
4 hours hypoxia Normoxia Normoxia Normoxia
4 hours hypoxia Hypoxia Hypoxia Hypoxia
5 days hypoxia Normoxia Normoxia Normoxia
5 days hypoxia Hypoxia Hypoxia Hypoxia
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brought to the laminar flow hood. Following drug treat-
ment, the cells were immediately returned to the hypoxia
chamber.
MTT Assay
Initial experiments were carried out to determine the
appropriate seeding density and drug treatment length.
Cells were plated in 100 μL of medium and left
overnight to attach. The following morning, they were
treated with cisplatin at varying concentrations for
3 days. Following treatment, response was measured via
an MTT assay carried out in accordance with the manu-
facturer’s instructions (Roche, UK). Absorbance was read
at 570 nm on an optical plate reader (Dynex Technolo-
gies, US). The absorbance detected was directly propor-
tional to the number of live cells present.
Protein preparation and quantification
A timecourse of HIF-1α protein expression was carried
out to monitor its levels during hypoxic exposure. Protein
was extracted in normoxia, and following 4 h, 3 days and
5 days of exposure to hypoxia. Cells were scraped into ice-
cold phosphate buffered saline (PBS, Lonza, UK), spun
down and lysed with ice-cold radioimmunoprecipitation
(RIPA) buffer (Sigma, UK) supplemented with 1 % prote-
ase inhibitor (Sigma, UK), 1 % phosphatase inhibitor
(Sigma, UK) and 2 mM phenylmethanesulfonylfluroride
(PMSF, Sigma, UK). For hypoxic protein extractions, PBS
and lysis buffer were allowed to equilibrate in the hypoxia
chamber, removed in a sealed container shortly before ex-
traction, and placed on ice. Protein was prepared from
hypoxic samples within the hypoxia chamber. A positive
control for HIF-1α expression was prepared by exposing
A2780 cells to 50 μM CoCl2, a hypoxia mimetic which
stabilizes HIF-1α protein in normal oxygen, for 24 h. Pro-
tein was quantified with the bicinchoninic acid (BCA)
assay; samples were stored at −20 °C.
Sodium dodecyl sulphate-polyacrylamide gel
electrophoresis (SDS-PAGE) and western blotting
The prepared protein (30 μg) was electrophoresed on
12 % gels; wet transfer was used to transfer protein from
the gels to nitrocellulose membranes (Biorad, Ireland).
The membranes were blocked with 5 % skimmed milk in
PBS (Oxoid, Thermofisher, Denmark) 0.1 % Tween
(Sigma, UK) for 2 h on an orbital shaker (Stuart Scientific,
UK) at 4 °C, then probed with mouse α-HIF-1α (1:250,
Clone 54, BD Biosciences, UK) in 3 % skimmed milk over-
night at 4 °C. The following day the membranes were
washed in PBS 0.3 % Tween, and probed with horse radish
peroxidise (HRP)-conjugated α-mouse (1:1,000, Cat.
A6782, Sigma, UK) for 1 h at room temperature. Blots
were incubated with Amersham ECL Advance (GE
Healthcare, UK) for 1 min and chemiluminescent images
were acquired using a Fuji Luminescent image analyzer
LAS-4000. The probes were then blocked again for 2 h at
4 °C and incubated with β-actin (1:10,000, Cat. A5441
Sigma, UK) overnight at 4 °C. The following day, the blots
were washed in PBS 0.3 % Tween and probed with AP-
conjugated α-mouse (1:1,000, Cat. A4312, Sigma, UK).
RNA Extraction
RNA was extracted from cell lines using the RNeasy
Mini kit (Qiagen, UK) according to the manufacturer’s
instructions. Eluted RNA was stored at −80 °C. RNA
yield was assessed using the NanoDrop (Thermofisher,
Fig. 1 Hypoxia matrix treatment pathway. In the pre-treatment phase, cells received no, acute or chronic hypoxia. During treatment, cells that
had prior hypoxia exposure were either treated in normoxia or hypoxia. Cells that had no prior hypoxia exposure were treated in normoxia for
the full 3-day treatment period or in hypoxia for 1, 2 or 3 days, with any remaining treatment time in normoxia
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Denmark) and RNA quality was determined using the
Bioanalyzer (Agilent, US). RNA was extracted from for-
malin fixed paraffin embedded (FFPE) ovarian tumour
samples using the RNeasy FFPE kit (Qiagen, UK) ac-
cording to the manufacturer’s instructions. Sections were
stained with haematoxylin and eosin and pathologically
reviewed; if tumour cell density was >90 %, whole sec-
tions were used for extraction. If a significant stromal
component was present, the sections were macrodis-
sected to enrich for the epithelial tumour population.
Affymetrix array analysis
RNA was extracted from cells treated with cisplatin for
3 days in the presence and absence of hypoxia and inter-
rogated on microarrays. Three independent biological
replicates were interrogated for each condition:
 A2780 (normoxia, untreated)
 A2780 (hypoxia, untreated)
 A2780 (normoxia, cisplatin treated)
 A2780 (hypoxia, cisplatin treated)
 A2780cis (normoxia, untreated)
 A2780cis (hypoxia, untreated)
 A2780cis (normoxia, cisplatin treated)
 A2780cis (hypoxia, cisplatin treated)
In total, 24 arrays were carried out. All samples run on
the arrays had an RNA Integrity Number (RIN) > 9.5 (Bioa-
nalyzer, Agilent, USA), indicating that the RNA was of high
quality. Samples were prepared according to the manufac-
turer’s instructions. Quality control metrics were carried
out based on the Affymetrix quality control white paper
[27]. Data was analysed using the Bioconductor libraries
‘oligo’, ‘limma’ and ‘made4’ [28–30]. Data was normalized
using the robust multi array average (RMA) method [31]
and statistical differences in gene expression across arrays
was determined using limma. A fold change ≥2 and false
discovery rate (FDR) < 0.05 was determined as significant.
Pathway analysis was carried out on lists of genes which
were determined as significant using DAVID v6.7 [32, 33].
Individual gene function and interaction was determined
using PubMed and the online tool information hyperlinked
over proteins (iHOP) [34]. Microarray data are available in
the ArrayExpress database (www.ebi.ac.uk/arrayexpress)
under accession number E-MTAB-3645.
Taqman PCR
Expression of potential markers of chemoresistance in
ovarian cancer selected following analysis of gene lists
from the Affymetrix analysis was determined using Taq-
man PCR in a cohort of ovarian tumour samples. RNA
was extracted from 35 serous adenocarcinomas of mixed
stage and grade (Table 1). cDNA was created using the
High Capacity RNA-to-cDNA kit (ABI, USA) and
Taqman PCR was carried out using Applied Biosystems
Universal Master Mix II (without UNG) and Gene Ex-
pression Assays. Gene expression was determined for
ANGPTL4, HER3 (ERBB3) and HIF-1α. Glyceraldehyde
3-phosphate dehydrogenase (GAPDH) was used as an
endogenous control. Relative gene expression was deter-
mined using the comparative CT method (2
-ΔΔCT) [35].
Statistical analyses
All experiments were carried out for n = 3. For MTT
assay experiments, response to cisplatin was measured
by changes in the inhibitory concentration 50 (the con-
centration of drug required to kill 50 % of cells, IC50).
Results were plotted using GraphPad Prism Software,
Version 5.03 (GraphPad Software Inc., USA). Non-linear
regression was used to analyse the growth curves. 100 %
was set as the average absorbance of untreated cells, and
all other points on the graph were calculated with the
following equation:
%Survival ¼ Absorbance of Treated Cells
Absorbance of Untreated Cells
 100
Student’s t-tests on the IC50 values were used to com-
pare the IC50 values at different points of the matrix.
Significance was set at p < 0.05.
For the microarray analysis, Limma was used to deter-
mine significant differences in gene expression. Signifi-
cance was set at a fold-change ≥ 2, with an FDR < 0.05.
For Taqman analysis of changes in gene expression, fold
changes in gene expression were calculated using the
2-ΔΔCT method. Individual fold-changes for each of the
responder samples were calculated by subtracting the
ΔCT (gene expression CT normalised to the endogenous
control, GAPDH) for each sample from the average ΔCT
for the group to obtain ΔΔCT and was entered into the
formula 2-ΔΔCT to obtain the fold change in order to
evaluate the variance among the responders. In partial
and non-responders, ΔCT was obtained by subtracting
the ΔCT for each sample from the average ΔCT for re-
sponders to obtain ΔΔCT. Unpaired two-sample t-tests
were carried out on the fold changes for partial and
non-responders vs responders to determine significant
changes in gene expression, p < 0.05.
Results
Acute hypoxia induces resistance to cisplatin in A2780
and A2780cis
A2780cis had a significantly higher IC50 for cisplatin
than A2870, p < 0.001 (Fig. 2a). In A2780 cells, exposure
to hypoxia for 4 h before treatment, followed by treat-
ment with cisplatin in hypoxia resulted in an 8-fold
increase in IC50 compared with normoxic cells (Fig. 2b),
p < 0.001. If the acutely hypoxic A2780 cells were treated
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with cisplatin in normoxia, the resistance was reduced
to 2.4-fold, however, this was still significant when com-
pared to the normoxic cells (p < 0.01). A2780cis cells
that were exposed to acute hypoxia prior to treatment in
hypoxia displayed a further 2-fold increase in resistance
to cisplatin which was significant p < 0.05 (Fig. 2c). How-
ever, if cells were removed from hypoxia for the treat-
ment period, the resistance level was equivalent with
that of normoxic cells.
Chronic hypoxia induces resistance to cisplatin in A2780
and A2780cis
Pre-exposing A2780 cells to chronic hypoxia (5 days)
followed by treatment with cisplatin in hypoxia resulted
in almost a 10-fold increase in IC50 (Fig. 3a) (p < 0.001).
Cells that were chronically exposed to hypoxia but
treated with cisplatin in normoxia showed comparable
sensitivity to hypoxia as non-hypoxic cells. Pre-exposing
A2780cis cells to hypoxia for 5 days before treatment
with cisplatin in hypoxia resulted in a 10 % increase in
resistance (Fig. 3b) (p < 0.05). This increase was only sta-
tistically significant when cells were both pre-exposed to
hypoxia and treated with cisplatin in hypoxia.
Treating A2780 and A2780cis in hypoxia increases
resistance to cisplatin
A2780 cells which were grown in normoxia and treated
in hypoxia (hypoxia naïve cells) showed increased resist-
ance to cisplatin (Fig. 3c). Cells which had the full 3-day
treatment in hypoxia showed levels of resistance which
were comparable with the resistance seen in the cells
which had been chronically exposed to hypoxia prior to
drug treatment in hypoxia. The level of resistance in
A2780 cells increased with increasing length of time in
hypoxia during the drug treatment. Hypoxia naïve
A2780cis cells which were treated with cisplatin in hyp-
oxia also demonstrated increased resistance to cisplatin
(Fig. 3d).
Patterns of HIF-1α protein expression in hypoxia in A2780
and A2780cis
HIF-1α protein was undetectable in both cell lines in
normal oxygen conditions (Fig. 3e). However, protein
was expressed from 4 h hypoxia exposure in both cell
lines. Levels of HIF-1α fluctuated slightly over time, with
an increase in HIF-1α protein expression observed at
3 days in A2780, but a decrease in HIF-1α protein ex-
pression observed in A2780cis.
Whole genome comparison of A2780 and A2780cis
In total, 1202 genes were differentially expressed in
A2780cis compared to A2780. Of these, 511 were up-
regulated and 691 were down-regulated. Gene expres-
sion changes are graphically represented on heat map
and chromosomal location plot (Additional file 1: Figure
S1A, D). Pathway analysis on Database for Annotation
Visualization and Individual Discovery (DAVID) revealed
the top up-regulated pathways as gap junction, cancer
pathways and intra-cellular signalling (Table 3), while
top down-regulated pathways include adhesion pathways
(Table 4).
Hypoxia induces common pathways in A2780 and
A2780cis
In A2780 and A2780cis, 914 genes were commonly al-
tered in response to treatment with cisplatin in hypoxia.
Chromosomal location plots display the location of al-
terations in gene expression while heat maps graphically
represent the differential gene expression (Additional file
1: Figure S1B, C, E, F). Similar pathways were altered in
both cell lines in response to hypoxia. In both cell lines,
the top up-regulated pathways included focal adhesion
and mitogen activated protein (MAP) kinase signalling,
while the top down-regulated pathways included DNA
replication, cell cycle and base excision repair (Table 5).
We found down-regulation of cell cycle molecules in-
cluding CDC25A, DNA replication genes including the
minichromosome maintenance proteins (MCMs) and
A B C
Fig. 2 Response of A2780 and A2780cis to Cisplatin following Acute Hypoxia. a. A2780cis were 9-fold more resistant to cisplatin in normal
oxygen. b. Following acute hypoxia, A2780 cells were 8-fold more resistant to cisplatin if the treatment was also carried out in hypoxia. This was
attenuated (2.4-fold) if the treatment was carried out in normoxia. c. A2780cis were approximately 2-fold more resistant to cisplatin following
acute hypoxia if the treatment was carried out in hypoxia. When acutely hypoxic A2780cis were placed in normal oxygen for the treatment
period, the resistance returned to the same level as cells which were never exposed to hypoxia. n = 3 *p < 0.05 ***p < 0.001
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pyrimidine metabolism genes in both cell lines when
exposed to hypoxia. When A2780 cells exposed to
hypoxia (hypoxia-induced resistance) were compared
with A2780cis cells (A2780 cells exposed to repeated
cisplatin exposure, cisplatin-induced resistance), 128
genes were commonly altered. From this commonly al-
tered gene list, the MAP kinase signalling pathway was
again found to be significantly enriched, while DNA
replication was down-regulated.
Genetic alterations in the ‘hypoxic Only’ response to
cisplatin
The gene expression differences in A2780 and A2780cis
in response to cisplatin were compared in normoxia and
hypoxia. We then looked at the ‘hypoxic only’ response
i.e. the genes which were altered in response to cisplatin
in hypoxia but not normoxia, as these may account for
some of the increased resistance to cisplatin observed in
hypoxia. Pathway analysis of these genes in A2780 re-
vealed that there was up-regulation of apoptotic path-
ways, ATP-binding cassette (ABC) transporters and
cancer pathways, while in A2780cis there was up-
regulation of the focal adhesion pathway. In both cell
lines there was down-regulation of the systemic lupus
erythematosus pathway, containing histone encoding
genes as well as down-regulation of cell cycle and erbb
signalling (A2780) and homologous recombination and
amino acid degradation pathways (A2780cis) (Table 6).
Hypoxia-associated biomarker selection
Potential novel biomarkers of hypoxia in ovarian cancer
were identified from the gene lists generated by Affyme-
trix analysis by thorough literature searching of their ex-
pression and significance in ovarian cancer and others.
Two potentially novel biomarkers of hypoxia in ovarian
A
E
B C D
Fig. 3 Response of A2780 and A2780cis to chronic hypoxia and hypoxia during treatment. a. A2780 cells exposed to chronic hypoxia before
treatment with cisplatin resulted in a 10-fold increase in resistance when the treatment was also carried out in hypoxia. The resistance returned
to that of normoxia when the chronically hypoxic cells were returned to normal oxygen for the treatment period. b. A2780cis displayed more
modest changes in resistance (<2-fold) following hypoxia although this was still significant. c. Hypoxia naïve cells (cells not exposed to hypoxia
before treatment) were exposed to hypoxia during cisplatin treatment for all or part of the 72 h treatment period for A2780. d. Hypoxia naïve cells
(cells not exposed to hypoxia before treatment) were exposed to hypoxia during cisplatin treatment for all or part of the 72 h treatment period
for and A2780cis. Both cell lines developed resistance when cells were challenged with cisplatin and hypoxia at the same time without any
previous exposure, although the fold changes were more modest in A2780cis. e. Timecourse of HIF-1α protein expression (120 kDa). Loading
control β-actin also shown (42 kDa). HIF-1α protein was absent in normoxia in A2780 and A2780cis. The levels fluctuated slightly over time, with
an increase in HIF-1α expression at 3 days in A2780 and a decrease in HIF-1α expression in A2780cis at 3 days. A2780 cells were exposed to
50 μM CoCl2 for 24 h for a positive control. n = 3 *p < 0.05 **p < 0.01 ***p < 0.001
Table 3 Significantly up-regulated pathways in A2780cis
compared to A2780
Pathway Genes P-value
Gap Junction GNAI1, GUCY1A3, GUCY1B3,ITPR3,
PDGFC, PDGFA, PrKCA, PrKCB,
TUBB4
0.005
Pathways in
Cancer
Fas, Jak1, KITLG, AR, ARNT2, CTNNA3,
FGF1, FGF10, FGFR2, ITGA6, Jun, PPARγ,
PLD1, VEGFC
0.01
Calcium
Signalling
ATP2B4, CHRNA7, CACNA1H, CAMK4,
CYSLTR2, GNAL, PTGER3, P2RX5,
ERBB3
0.02
PPAR Signalling CD36, ACSL1, CPT1A, FABP5, MMP1,
SLC27a2
0.02
Long-term
depression
PLA2G3 0.02
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cancer were selected – angiopoietin like protein 4
(ANGPTL4, up-regulated in both A2780 and A2780cis
in response to hypoxia exposure) and human epidermal
growth factor receptor 3 (HER3, up-regulated in
A2780cis compared to A2780, and in hypoxic A2780
compared to normoxic A2780 while down-regulated in
the A2780cis ‘hypoxic only’ response to cisplatin.
Biomarker expression in serous papillary adenocarcinoma
Expression of ANGPTL4, HER3 and HIF-1α was examined
in 35 serous papillary carcinomas. The patient/tumour
characteristics are described in Table 1. ANGPTL4 demon-
strated a trend for up-regulation in partial responders and
down-regulation in non-responders to chemotherapy com-
pared to responders (Fig. 4a). HER3 trended towards
down-regulation in both partial and non-responders to
chemotherapy compared to responders (Fig. 4b), while
HIF-1α appeared unchanged in partial responders and
trended towards down-regulation in non-responders to
chemotherapy compared to responders (Fig. 4c).
Discussion
We developed a hypoxia matrix in order to best repre-
sent possible clinical scenarios in patient care. We con-
sidered four types of patient:
 A patient with a small tumour which has not been
hypoxic before or during chemotherapy (normoxia)
 A patient with a large tumour receiving neoadjuvant
chemotherapy before debulking surgery (pre-
exposure to acute/chronic hypoxia, treatment in
hypoxia)
Table 4 Significantly down-regulated pathways in A2780cis
compared to A2780
Pathway Genes P-value
Focal Adhesion FYN, SHC4, ACTN3, CAV1, CAV2,
COL1A2, COL6A3, FLNC, HGF,
IGF1R, ITGA5, ITGA8, LAMA1,
PIK3CA, PDGFD, PDGFA, SPP1,
THBS1, AKT3, VAV3, VCL
<0.0001
Arrhythmogenic Right
Ventricular
Cardiomyopathy
CDH2, CACNG7, DSC2, DSG2,
DMD, CACNA1C, JUP, SLC8a1,
TCF7L1
<0.0001
Melanoma CDKN2A, FGF18, FGF20, FGF5 0.001
Axon Guidance EPHA3, EPHA7, NTNG1, PLXNC1,
ROBO2, SEMA3E, SEMA6A, SEMA6D,
SLIT2, UNC5C
0.006
Cell Adhesion Molecules CDH2, CLDN17, CLDN8, CNTNAPA2,
HLA-DPA1, HLA-DRB3, NEO1,
NLGN4X, NEGR1, SDC2, VCAN
0.006
Table 5 Pathway analysis of genetic changes in A2780 and
A2780cis in response to hypoxia
Cell Line Pathway P-value Change in
Expression
A2780 MAPK signalling 0.001 Up-Regulated
Focal adhesion 0.002
Renal Cell Carcinoma 0.01
Starch and Sucrose Metabolism 0.04
Complement and Coagulation
Cascade
0.04
A2780cis MAPK signalling 0.02
Focal adhesion <0.001
Axon guidance 0.002
TGF beta signalling 0.007
Toll like receptor signalling 0.02
DNA replication <0.001
A2780 Cell cycle <0.001 Down-regulated
Pyrimidine metabolism <0.001
Base Excision Repair <0.001
Homologous Recombination <0.001
DNA replication <0.001
A2780cis Cell cycle <0.001
Pyrimidine metabolism 0.001
Base excision repair 0.004
Oxidative phosphorylation <0.001
Table 6 Pathway analysis of genetic changes in the ‘hypoxic
only’ response to cisplatin in A2780 and A2780cis
Cell Line Pathway P-value Change in
Expression
A2780 Apoptosis 0.001 Up-regulated
ABC Transporters 0.002
Amyotrophic Lateral Sclerosis 0.005
Small Cell Lung Cancer 0.02
p53 signalling 0.02
Pancreatic Cancer 0.02
Chronic Myeloid Leukemia 0.03
A2780cis Focal Adhesion 0.04
A2780 Systemic Lupus Erythematosus 0.02 Down-regulated
MAPK signalling <0.001
Cell Cycle 0.002
Steroid Biosynthesis 0.005
ErbB Signalling 0.01
Nitrogen Metabolism 0.02
Axon Guidance 0.02
Colorectal Cancer 0.03
Gap Junction 0.04
A2780cis Systemic Lupus Erythematosus <0.001
Valine, Leucine and Isoleucine
degradation
0.004
Homologous Recombination 0.03
Oocyte meiosis 0.05
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 A patient with a large tumour removed before
receiving adjuvant chemotherapy (pre-exposure to
acute/chronic hypoxia, treatment in normoxia)
 A patient with a tumour undergoing transient
hypoxia due to abnormal vasculature and
compression of blood vessels (all matrix conditions
that included exposure to hypoxia)
Exposing both A2780 and A2780cis to acute or
chronic hypoxia before treating with cisplatin increased
resistance to cisplatin, but only if the treatment period
was also carried out in hypoxia. This indicated that the
resistance which could be induced by hypoxia was
quickly reversible when the cells were moved back into
normal oxygen. Reoxygenation following hypoxic expos-
ure has been shown to restore sensitivity to radiation
therapy in breast cancer [36] and gastric cancer [37],
and a previous study in breast cancer has shown that
cells exposed to hypoxia followed by drug treatment in
normal oxygen displayed no resistance to cisplatin [38].
We found that by exposing the cells to hypoxia during
treatment without any prior hypoxia exposure, the cells
had similar resistance levels to those which had under-
gone chronic pre-exposure to hypoxia, indicating that the
most important factor determining chemoresistance is the
presence of hypoxia at the time of treatment, rather than
prior exposure. This indicates a potential role for hypoxia-
targeted agents in combination with standard chemother-
apy regimens. This may be particularly important in pa-
tients undergoing neoadjuvant chemotherapy, as these
patients often have large tumours that may be hypoxic.
The mechanisms underlying the platinum resistance
observed in A2780cis have not been fully identified.
Upregulation of cell proliferation markers [39], members
of the Akt signalling pathway [40, 41], DNA-repair mech-
anisms [26] and ATP-dependent processes [42], and re-
duction in the copper transporter CTR1, thus preventing
platinum accumulation [43] are among the suggested in-
fluences. We compared A2780 and A2780cis at the whole
genome level in order to further identify mechanisms by
which A2780cis has become resistant to cisplatin. Large
differences in gene expression were observed as shown in
the heat map (Additional file 1: Figure S1). We found up-
regulation of p53 pathway signalling, a pathway that has
been implicated in response to DNA damage [44]. In
addition, we found down-regulation of other gene families
linked to chemoresistance including several of the ATP-
ase transporters and glutathione peroxidise 8. Knockdown
of glutathione peroxidise 3 has been shown to increase
platinum sensitivity in ovarian cancer clear cell carcinoma
[45]. Other genes identified in the current study which
may contribute to the cisplatin resistance of A2780cis in-
cluded up-regulation of PDGF isoforms such as PDGFC
which has been previously linked to cisplatin resistance in
head and neck squamous cell carcinoma cell lines [46].
Janus kinase (Jak) 1, the tyrosine kinase protein which has
been linked to cisplatin resistance in breast carcinoma
[47] and ovarian cancer [48] was also up-regulated in
A2780cis. Caveolin 1 (CAV1), was found to be down-
regulated in A2780cis. Low CAV1 expression has been
linked to cisplatin resistance in oral squamous cell carcin-
oma [49] while it is a putative tumour suppressor candi-
date in ovarian cancer [50].
We found that common pathways were significantly
enriched in both cell lines in response to hypoxia, al-
though not necessarily the same genes. Far more genes
A B C
Fig. 4 Expression of potential and known hypoxia biomarkers in ovarian cancer samples. The expression of ANGPTL4 (a), HER3 (b) and HIF1α (c)
was examined in 35 serous ovarian adenocarcinoma samples. The samples were divided into responders (n = 16), partial responders (n = 11) and
non-responders (n = 8). Expression of ANGPTL4 trended towards up-regulation in partial and down-regulation in non-responders compared to
responders to chemotherapy. Expression of HER3 trended towards down-regulation in partial and non-responders to chemotherapy compared to
responders. Expression of HIF-1α trended towards down-regulation in non-responders compared to responders to chemotherapy. There were
missing data in one patient for HER3 expression and in three patients for ANGPTL4 expression in the responder group; and in one patient for
ANGPTL4 expression in the non-responder group
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were down-regulated in A2780 cells in response to hyp-
oxia compared with A2780cis as can be seen on the
chromosomal location plots (Additional file 1: Figure S1).
Genes linked to cellular proliferation were markedly
down-regulated in both cell lines. Chemotherapy drugs
generally target actively dividing cells and reduced cell
proliferation has been suggested as a mechanism of che-
moresistance [51]. We found reduced expression of cell
cycle markers, DNA replication markers and metabolic
markers in both A2780 and A2780cis cells that were ex-
posed to hypoxia, which may have contributed to the re-
sistance observed. Low cellular proliferation has been
linked to chemoresistance in clear cell carcinoma of the
ovary [52, 53]. Despite being amenable to surgical exci-
sion, low grade ovarian serous tumours (characterised by
a low mitotic index) have been shown to be relatively re-
sistant to chemotherapy [54]. Approximately 1,000 fewer
genes altered in hypoxia in A2780cis compared to A2780,
suggesting that some of the changes induced by hypoxia
in A2780 may have already been induced in A2780cis
through cisplatin exposure. In addition, 128 genes which
were altered by hypoxia in A2780 were already changed in
A2780cis.
We did not see any change in HIF-1α expression in
response to hypoxia at the gene level in the arrays,
however, HIF-1α is known to be regulated at the pro-
tein level [55] and we had found that HIF-1α protein
was increased in response to hypoxia in these cell
lines. In addition, we did see up-regulation of surro-
gate hypoxic markers in hypoxia-exposed cells such
as GLUT-1 (2.61-fold in A2780) and CA9 (20.42-fold
in A2780 and 4.18-fold in A2780cis). We identified
many genes altered in response to hypoxia in our cell
line model which have been previously linked to plat-
inum resistance in the literature including comple-
ment decay accelerating factor (CD55) [56] and tissue
inhibitor of metallopeptidases 3 (TIMP3) [57]. We
looked at the differences in genetic response to cis-
platin in normoxia and hypoxia in both cell lines, and
mainly focused on the changes which occurred in
hypoxia which did not occur in normoxia, as these
are likely linked to the platinum resistance which oc-
curred when the cells were exposed to hypoxia. We
found many potential biomarkers of platinum resist-
ance in hypoxia including NOTCH1 [58] which has
been identified as a potential therapeutic target in
ovarian cancer [59, 60].
We carried out a comprehensive literature search of
the genes which we identified on our array analysis in
order to identify markers which could serve as novel
markers of hypoxia and/or platinum resistance in
ovarian cancer. We chose ANGPTL4 and HER3 to
follow up in a cohort of ovarian tumour samples. Pre-
vious studies [61–64] have indicated a negative role
for ANGPTL4 in other cancer types, and ANGPTL4
has previously been shown to be activated by HIF-1α
[65] and to confer protection against hypoxia-induced
apoptosis in cell lines. However, there was little infor-
mation available regarding its role in ovarian cancer
and platinum resistance. HER3 has previously been
identified as a potential therapeutic target in ovarian
cancer and has been linked to sensitivity to monoclonal
antibody therapy with gefitinib [66] and pertuzumab [67].
Gastric adenocarcinoma cells knocked down for HER3
have shown increased sensitivity to cisplatin [68]. How-
ever, little is known about the influence of hypoxia on
HER3 expression. In addition, we evaluated HIF-1α ex-
pression, a universal marker of hypoxia.
ANGPTL4 is an angiogenesis-associated protein which
has many functions including prevention of apoptosis
[69], induction of angiogenesis [70], inhibition of angio-
genesis [71] and facilitation of metastasis [72]. We found
it to trend towards up-regulation in partial responders
to chemotherapy compared to responders. This was a
novel finding, as there is no information in the literature
regarding ANGPTL4 expression in serous ovarian cancer.
The exact function of ANGPTL4 in ovarian carcinogen-
esis is unclear; it may be that the function of ANGPTL4 is
dependent on the level of transcript present and the
tumour type it is expressed in.
HER3 is a member of the epidermal growth factor re-
ceptor family [73] and has been linked to resistance to a
number of therapeutics such as gefitinib in lung cancer
[74] and paclitaxel in breast cancer [75]. Unexpectedly, we
found HER3 expression to trend towards down-regulation
in partial responders and non-responders to chemother-
apy compared to responders. This was unusual, as high
HER3 expression is usually linked to more aggressive
tumour features such as metastasis [76] and reduced
survival [77]. However, a recent study investigating the
process of epithelial to mesenchymal transition (EMT)
in ovarian cancer cell lines found low HER3 expression
in intermediate mesenchymal cells, cells which had a
more aggressive phenotype due to resistance to anoikis
(a form of programmed cell death) and increased
spheroid-forming capability in vitro [78]; hypoxia has
been shown to induce EMT in ovarian cancer cells
[22]. It may be that an unknown molecule is negatively
regulating HER3 expression in our population, or that
subclones of cells are responsible for the overall effect
of differing HER3 expression. Indeed, it has been recog-
nised that tumour sampling is very important in mo-
lecular analyses due to intra-tumour heterogeneity [79],
and the regions sampled in our study may not have
been representative of the whole tumour. Interestingly,
low HER3 expression may identify patients who are suit-
able for alternate forms of treatment such as α-tocopherol
ether-linked acetic acid (α-TEA) [80].
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Conclusions
Overall, these results show that the most important de-
termining factor for development of resistance is the
presence of hypoxia during the treatment period, not
prior to treatment thus highlighting the potential im-
portance of simultaneously reducing tumour hypoxia
and treating with chemotherapy. This may have particu-
lar importance in patients with large tumours who re-
ceive neoadjuvant chemotherapy. A number of pathways
are responsible for the resistance to cisplatin observed
due to hypoxia, and that there are many candidate bio-
markers of hypoxia which could be explored in the con-
text of ovarian cancer. We have also provided an initial
validation of selected hypoxia-associated biomarkers in
ovarian tumour samples. It will be important to expand
the study and to validate these results at the protein
level in future studies in order to elucidate their true
importance.
Additional file
Additional file 1: Figure S1. Graphical representation of genetic
changes in A2780 and A2780cis. Chromosomal location plots depicting
location of differentially expressed genes in A2780cis compared to A2780
(A) and in response to hypoxia in A2780 (B) and A2780cis (C). Genes
up-regulated are depicted in yellow, down-regulated in red and unchanged
in white. Heat maps displaying patterns of differential gene expression in
A2780cis compared to A2780 (D), and in response to hypoxia in A2780 (E)
and A2780cis (F). Up-regulated genes are depicted in yellow, and
down-regulated in red. n = 3.
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